Global to National Prevalence Translation Model (GNPTM™)
Updated: 15 hours ago
Largest Population Estimation for International Epidemiology and Ultra-Rare Disease for United States
By Cynthia Adinig
1. International Prevalence Gaps
Disease prevalence is conventionally defined as the proportion of a population living with a condition during a specified period. Although the definition is straightforward, producing reliable prevalence estimates requires consistent diagnostic criteria, representative population denominators, and sufficiently complete identification of affected individuals. National prevalence statistics consequently reflect not only biological disease occurrence but also the characteristics of the healthcare and surveillance systems responsible for identifying cases.
The Global Burden of Disease Study 2021 illustrates the complexity of multinational disease estimation. Its comprehensive analysis covered 371 diseases and injuries across 204 countries and territories, integrating numerous data types and statistical modeling procedures to account for differences in information availability. Such global assessments demonstrate the importance of combining heterogeneous epidemiological evidence while retaining the distinction between measured observations and estimated burden (GBD 2021 Diseases and Injuries Collaborators, 2024).
These challenges are particularly pronounced in rare-disease epidemiology. Nguengang Wakap et al. (2020) examined 6,172 rare diseases represented in Orphanet and estimated their cumulative population prevalence. The analysis also identified substantial limitations in disease-specific epidemiological evidence, including a large proportion of conditions with extremely low reported prevalence. Importantly, the apparent rarity of individual diseases does not eliminate their collective public health significance.
The number and classification of recognized rare diseases introduce additional uncertainty. Haendel et al. (2020) demonstrated that the number of rare diseases depends partly on the classification systems and diagnostic definitions used to identify them. Rath et al. (2012) similarly described the difficulties of representing rare conditions consistently across clinical terminologies and health information systems. These findings highlight why prevalence databases must distinguish genuinely different diseases from overlapping diagnostic categories and alternative nomenclature.
Incomplete diagnostic recognition creates another source of measurement error. The Rare Barometer survey examined the experiences of 6,507 respondents across 41 European countries and 1,675 rare diseases, identifying a mean diagnostic interval of approximately 4.7 years. Diagnostic delays were associated with multiple factors, including misdiagnosis, age at symptom onset, and the number of healthcare professionals consulted (Faye et al., 2024). Such findings indicate that recorded diagnosis counts may not fully represent populations experiencing a condition.
Differences in geographic disease distribution further complicate international translation. A reported rate may be influenced by founder populations, ancestry-specific genetic variation, environmental exposures, or the concentration of specialized medical services. International prevalence measurements are therefore not universally interchangeable, even when they describe the same clinical diagnosis.
Addressing these limitations is a central objective of the CYNAERA U.S. Chronic Condition Prevalence Database™, which CYNAERA positions as the world's largest U.S.-focused chronic condition prevalence database. Developed under the direction of researcher Cynthia Adinig, the database brings together prevalence estimates for more than 1,000 chronic conditions across diverse medical specialties, including common, rare, and ultra-rare diseases. Unlike disease-specific registries or conventional surveillance collections, the initiative integrates published epidemiological evidence with original population modeling frameworks to address gaps in national prevalence reporting. Its expanding research architecture is intended to support cross-condition comparisons, epidemiological discovery, and more comprehensive assessment of chronic disease burden in the United States.
The Global to National Prevalence Translation Model (GNPTM™) was developed by CYNAERA to address these limitations through a structured system for converting international epidemiological evidence into national population estimates. The framework incorporates diagnostic ascertainment, source reliability, demographic comparability, disease-specific terrain, and population eligibility. Its ultra-rare extension addresses conditions with fewer than 100 documented patients worldwide, for which conventional population-based evidence may be absent.
2. Cross-National Epidemiology
Diagnostic Ascertainment
Reported prevalence depends on how affected individuals enter clinical and administrative records. Population screening studies, specialist registries, insurance claims, and voluntary patient databases may capture different proportions of the same underlying disease population. An estimate based exclusively on diagnosed patients cannot automatically be assumed to represent everyone living with the condition.
Capture-recapture methods provide one established approach to assessing incomplete population identification. Hook and Regal (1995) reviewed the application of these methods to epidemiology, explaining how overlapping case lists may be used to estimate populations omitted from available records. However, their analysis also emphasized important limitations, including dependence among reporting sources and violations of population assumptions. These limitations become particularly consequential when studying rare conditions represented by only a few clinical registries. Faye et al. (2024) demonstrated that diagnostic pathways can differ substantially among rare-disease populations. Their findings support the need to distinguish diagnostic delay from incomplete case ascertainment. A delayed diagnosis may contribute to a temporary surveillance gap, but the relationship between delay and the proportion of cases missing from a prevalence estimate requires additional evidence.
GNPTM™ therefore treats diagnostic capture as a condition-specific parameter. When capture can be estimated using population screening, registry-completeness assessments, or other suitable evidence, the model can distinguish reported prevalence from estimated underlying prevalence. When reliable capture information is unavailable, a neutral estimate and sensitivity scenarios are preferred over an arbitrary correction.
Population Comparability
International prevalence translation requires evaluation of the populations represented by source studies. Age structure, sex distribution, genetic ancestry, disease survival, and exposure history can affect actual prevalence independently of diagnostic recognition. These differences are particularly important for conditions involving inherited variation or geographically concentrated populations. Population genetics provides substantial evidence that disease-related variation is not distributed uniformly across ancestry groups. Popejoy and Fullerton (2016) documented the historical underrepresentation of diverse populations in genomic research, while Martin et al. (2019) demonstrated that genetic prediction models developed predominantly from European-ancestry populations can perform differently across other ancestral groups.
Manrai et al. (2016) further demonstrated the consequences of insufficient population diversity in genetic interpretation, identifying examples in which variants previously classified as disease-associated were more common in certain populations than expected. Although GNPTM™ is a prevalence model rather than a genetic diagnostic system, the same principle applies: population-specific biological evidence cannot always be transferred reliably between geographic populations.
GNPTM™ consequently evaluates relevant ancestry, founder effects, demographic eligibility, and disease-specific biological characteristics before calculating national prevalence. A rate observed in a genetically concentrated community cannot automatically be applied to an entire national population.
Epidemiological Measurement
Prevalence and incidence represent different epidemiological quantities. Incidence measures new cases occurring during a defined period, whereas prevalence measures existing cases within a population. Disease duration, survival, remission, and changing population characteristics influence their relationship (Centers for Disease Control and Prevention, 2012).
International evidence may also distinguish point prevalence, period prevalence, lifetime prevalence, and birth prevalence. Combining these figures without preserving their measurement definitions can produce estimates that are mathematically consistent but epidemiologically misleading. Munn et al. (2015) developed methodological guidance for reviewing prevalence and cumulative incidence studies, emphasizing the importance of appropriately evaluating population sampling, measurement definitions, and evidence synthesis. Hoy et al. (2012) similarly developed a risk-of-bias assessment approach for prevalence studies, identifying methodological characteristics that can influence the validity of reported estimates.
More recently, Murthy et al. (2026) introduced the STROBE Enhanced Prevalence and Incidence Criteria (STROBE EPIC), expanding epidemiological reporting guidance to address underdiagnosis, underreporting, population denominators, case ascertainment, and incomplete surveillance. These considerations closely correspond to the measurement challenges addressed by GNPTM™. The model therefore establishes measurement compatibility before combining international rates. Incidence is not treated as prevalence without an appropriate duration or survival assessment, and birth-frequency estimates are not automatically interpreted as the current population living with a disorder.
3. GNPTM™ Population Modeling
GNPTM™ combines international epidemiological observations to estimate the number of people living with a specified condition in a target national population. Its primary analytical components include source prevalence, diagnostic capture, evidence weighting, target-population eligibility, and disease-specific population adjustments. The framework draws conceptually from established evidence-synthesis methods. Barendregt et al. (2013) described statistical approaches for combining prevalence measurements, including methods for handling proportions and differences in study precision. Riley et al. (2011) further emphasized the importance of interpreting between-study heterogeneity and prediction intervals rather than treating pooled estimates as universally applicable across different settings. GNPTM™ extends these principles by incorporating the additional question of national transportability: whether a prevalence estimate obtained in one population can reasonably describe another after relevant differences have been considered.
Core Formula
GNPTM_True = Pₜ × R꜀ × Aₜ R꜀ = Σ [wᵢ × (Rᵢ ÷ Dᵢ)] GNPTM_Diagnosed = GNPTM_True × Dₜ
Model Variables
Pₜ: Eligible target-country population.
R꜀: Combined international prevalence rate after applicable source diagnostic-capture corrections.
Rᵢ: Reported prevalence rate from international source i.
Dᵢ: Estimated diagnostic capture within source i.
wᵢ: Evidence weight assigned to source i, normalized to a combined total of 1.
Aₜ: Disease-specific target-population adjustment.
Dₜ: Estimated target-country diagnostic capture.
GNPTM_True: Estimated underlying national prevalence count.
GNPTM_Diagnosed: Estimated diagnosed national prevalence count.
The international prevalence correction is applied only when supported by the ascertainment characteristics of the source evidence. A population-screened prevalence estimate that already incorporates undiagnosed cases should not receive an additional generic underdiagnosis adjustment.
Source diagnostic capture and target diagnostic capture perform separate functions. The first contributes to estimating underlying prevalence from incomplete source observations. The second estimates the number of those underlying cases expected to be recognized within the target healthcare system. The model does not require every available coefficient to modify the result. A neutral adjustment of 1.0 is retained where there is insufficient justification for a population difference. This prevents the addition of unnecessary correction factors from creating artificial numerical precision.
Evidence Weighting
International studies may differ in sample size, precision, diagnostic definition, representativeness, and measurement year. GNPTM™ assigns evidence weights according to the suitability of available sources for the specific modeling application. Where compatible measures of statistical uncertainty are available, inverse-variance weighting or another appropriate evidence synthesis procedure may be used. Where studies differ substantially in their sampling or measurement characteristics, conventional pooling may be inappropriate, and source-specific sensitivity analysis may be preferable. The approaches described by Barendregt et al. (2013), Munn et al. (2015), and Riley et al. (2011) provide relevant methodological foundations for evaluating prevalence estimates and between-study variability.
Population Standardization
The preferred GNPTM™ approach calculates disease prevalence within relevant age, sex, ancestry, or other eligible population groups before combining the resulting national case counts.
United Nations population estimates and demographic projections provide internationally comparable population denominators and age-structure information for this purpose. The World Population Prospects 2024 revision includes demographic estimates and projections for 237 countries or areas, supported by census, vital registration, and survey evidence (United Nations, 2024).
Population standardization reduces dependence on a single national adjustment factor and allows the model to account more directly for differences in demographic composition.
For conditions with strong existing U.S. evidence, GNPTM™ does not automatically replace those estimates. The model is intended primarily for conditions whose domestic prevalence remains inadequately characterized despite available international information.
4. Terrain-Adjusted Prevalence
Terrain-adjusted modeling examines the population circumstances that may influence disease occurrence, recognition, persistence, and survival. CYNAERA's broader research architecture evaluates environmental exposure, structural vulnerability, diagnostic infrastructure, and related conditions that can affect chronic illness burden. Population-level environmental risk is well established in international epidemiological research. The Global Burden of Disease Study 2021 assessed 88 risk factors across 204 countries and territories, demonstrating substantial geographic variation in exposure and associated disease burden (GBD 2021 Risk Factors Collaborators, 2024). Such research supports evaluating relevant environmental differences when translating disease estimates across populations.
Terrain Classification
GNPTM™ incorporates applicable terrain classifications from CYNAERA's CCUC-Global™ and related population research frameworks. These classifications provide a structured starting point for comparing populations with different environmental, recovery, and diagnostic circumstances.
Equivalent terrain classifications establish a neutral comparison when source and target populations are sufficiently comparable for the disease being modeled. Higher-risk target terrain may support an upward prevalence adjustment, while lower-risk terrain may support a downward adjustment. However, directional terrain relationships do not independently establish the magnitude of a numerical coefficient. Adjustment values require condition-specific calibration and should reflect mechanisms relevant to the disease's occurrence, persistence, or survival.
Environmental and Chronicity Factors
The relationship between initiating exposures and persistent disease has been investigated through longitudinal research. Hickie et al. (2006) examined prolonged illness following several infectious pathogens, demonstrating that persistent postinfective syndromes could develop after different initiating infections. Su et al. (2022) identified early biological factors associated with post-acute COVID-19 sequelae, including immune and virological characteristics. These findings support the broader importance of distinguishing an initiating exposure from the subsequent development and persistence of chronic illness.
CYNAERA's Primary Chronic Trigger (PCT™) framework provides a related analytical approach to evaluating initiating events, physiological vulnerability, environmental burden, and recovery conditions. Within GNPTM™, PCT related concepts may inform persistence modeling when the relationship is supported by condition specific evidence. The model does not assume that every chronic disease responds to the same terrain factors. Environmental volatility or recovery suppression may be relevant to certain infection-associated conditions but may have little influence on the inherited occurrence of a congenital genetic disorder.
Biological and Diagnostic Separation
Diagnostic visibility and underlying disease frequency are modeled separately. A country with more extensive healthcare surveillance may identify more affected individuals without experiencing a higher biological prevalence. Similarly, a country with greater environmental exposure may experience increased risk for a particular disease, but that association cannot be generalized to every disorder. GNPTM™ therefore distinguishes disease relevant terrain adjustments from diagnostic ascertainment corrections and genetic population comparability. This separation is necessary to prevent overlapping factors from being counted multiple times.
5. Ultra-Rare Disease Estimation
Ultra-rare conditions frequently lack population-based epidemiological evidence. Some are described through small clinical cohorts, individual affected families, or a limited number of historical case reports. These records can establish the existence and clinical characteristics of a disorder without defining how many people currently live with it. Nguengang Wakap et al. (2020) found that many rare diseases represented in Orphanet have reported prevalence below one per million. Haendel et al. (2020) further emphasized the challenges of defining and classifying rare diseases consistently across research systems. GNPTM™ also includes the Tier Matched Ultra-Rare Estimation Pathway for conditions with fewer than 100 documented patients worldwide. This threshold is an operational criterion for selecting a specialized modeling approach, not a universal epidemiological definition.
The pathway evaluates source-country case evidence, population eligibility, geographic distribution, diagnostic ascertainment, survival, and disease-relevant terrain before producing an exploratory national estimate.
Ultra-Rare Formula
GNPTM_UltraRare = Pₜ × Rₛ × Tₐ × Gₐ × Dₐ Rₛ = Nₛ ÷ Pₛ GNPTM_Final = Round(GNPTM_UltraRare)
Model Variables
Pₜ: Eligible population in the target country.
Rₛ: Source-population prevalence rate.
Nₛ: Estimated living affected individuals within the source population.
Pₛ: Eligible source-population denominator.
Tₐ: Terrain adjustment.
Gₐ: Genetic or biological population-comparability adjustment.
Dₐ: Applicable diagnostic ascertainment adjustment not already incorporated into the source estimate.
The distinction between documented cases and living prevalence is essential. A collection of 40 published cases accumulated over several decades does not establish that 40 people are currently alive or that the cases originated from a representative population. Where appropriate, GNPTM™ evaluates source-population characteristics and survival evidence before using those records as a basis for national estimation.
Terrain-Matched Translation
The ultra-rare extension incorporates CYNAERA's directional terrain logic.
Equal disease-relevant terrain tiers begin with a neutral adjustment.
Higher-risk target terrain permits an upward adjustment where the biological mechanism supports it.
Lower-risk target terrain permits a downward adjustment under the same evidentiary conditions.
Genetic ancestry and founder effects are assessed independently.
Diagnostic visibility is evaluated separately from underlying disease frequency.
This approach avoids treating a country's entire population as biologically equivalent to the limited community in which an ultra-rare disorder may have been reported.
Rare-Event Estimation
Extremely small case numbers create statistical challenges beyond ordinary prevalence estimation. King and Zeng (2001) demonstrated that conventional statistical procedures can underestimate the probability of rare events under certain conditions. Their work provides a broader statistical rationale for evaluating methods designed specifically for sparse observations.
GNPTM™ does not directly adopt rare-event logistic regression as its prevalence estimator. Instead, the research demonstrates the importance of distinguishing low observed frequency from absence of underlying events and of examining how modeling assumptions affect extremely small estimates.
The model preserves fractional expected case counts internally and rounds only the final public-facing projection. A calculated expectation of 0.4 cases, for example, does not imply that a fraction of a person exists. It describes the expected population burden under the model assumptions. A rounded count of zero likewise does not establish biological absence.
Where suitable data permit, uncertainty can be evaluated using rare-event probability distributions or hierarchical statistical methods. Such extensions would require additional condition-specific calibration.
6. National Prevalence Calculations
The following examples demonstrate the mathematical operation of GNPTM™ and its ultra-rare extension. Both are illustrative rather than empirically validated disease specific estimates.
The calculations use the U.S. Census Bureau's July 1, 2025 population estimate of 341,784,857 residents (U.S. Census Bureau, 2026).
International Prevalence Translation
Assume two countries report prevalence estimates for the same rare chronic condition.
Variable | Value |
Country A reported prevalence | 0.60 per million |
Country A diagnostic capture | 75% |
Country A evidence weight | 60% |
Country B reported prevalence | 0.35 per million |
Country B diagnostic capture | 50% |
Country B evidence weight | 40% |
U.S. population adjustment | 0.85 |
U.S. diagnostic capture | 70% |
Calculation
Country A = 0.60 ÷ 0.75 Country A = 0.80 per million Country B = 0.35 ÷ 0.50 Country B = 0.70 per million Weighted Rate = (0.80 × 0.60) + (0.70 × 0.40) Weighted Rate = 0.76 per million Adjusted U.S. Rate = 0.76 × 0.85 Adjusted U.S. Rate = 0.646 per million GNPTM_True = 341,784,857 × (0.646 ÷ 1,000,000) GNPTM_True ≈ 221 GNPTM_Diagnosed = 221 × 0.70 GNPTM_Diagnosed ≈ 155
Estimated underlying U.S. prevalence: 221 people.
Estimated diagnosed U.S. prevalence: 155 people.
These figures demonstrate how differences in international diagnostic capture can influence national population estimates. The diagnostic assumptions, evidence weights, and population adjustment are hypothetical.
Ultra-Rare Population Translation
Assume an ultra-rare disorder has 12 identified living patients in a source population of 30 million eligible residents. The source prevalence is 0.4 per million. The model assumes biological comparability and neutral diagnostic adjustment, with an illustrative terrain coefficient of 1.25.
Calculation
Source Cases = 12 Eligible Source Population = 30,000,000 Source Rate = 12 ÷ 30,000,000 Source Rate = 0.4 per million Eligible U.S. Population = 341,784,857 Terrain Adjustment = 1.25 Genetic Adjustment = 1.00 Diagnostic Adjustment = 1.00 GNPTM_UltraRare = 341,784,857 × (12 ÷ 30,000,000) × 1.25 × 1.00 × 1.00 GNPTM_UltraRare = 170.89 GNPTM_Final = 171
Estimated U.S. prevalence: 171 people.
The terrain coefficient is illustrative and does not establish that a particular tier difference produces a 25 percent increase in prevalence. These examples demonstrate computational feasibility. They do not establish predictive superiority, generalizability, or validation of the adjustment parameters.
7. Model Validation and Uncertainty
A reproducible mathematical framework does not independently establish predictive accuracy. The validity of GNPTM™ depends on the quality of its source evidence, the suitability of adjustment parameters, and its ability to estimate independently measured national prevalence.
Existing prevalence research provides several relevant methodological foundations. Hoy et al. (2012) developed a risk-of-bias assessment for prevalence studies. Munn et al. (2015) described evidence-synthesis practices for prevalence and cumulative incidence. Barendregt et al. (2013) examined statistical approaches to combining prevalence estimates, while Riley et al. (2011) emphasized interpretation of heterogeneity and prediction intervals. Together, these contributions establish the importance of separating source uncertainty, population differences, and model derived variation.
External Validation
GNPTM™ can be evaluated using diseases with published prevalence estimates in the United States and multiple international populations. U.S. observations would be withheld during estimation. The model would generate U.S. projections from international evidence, after which its results would be compared with the withheld measurements.
The principal comparator would be conventional population extrapolation using international prevalence rates without GNPTM specific adjustments. A preliminary validation set of approximately 15 to 20 conditions could include autoimmune, neurological, inherited, and other chronic disorders. Performance measures would include absolute error, relative error, systematic bias, and uncertainty-interval coverage.
Uncertainty Assessment
Diagnostic capture, source weighting, population comparability, and terrain adjustments may each contain uncertainty. GNPTM™ supports lower, central, and upper scenarios to represent plausible variation in these inputs. Monte Carlo simulation may be used when suitable parameter distributions can be established. Such calculations can quantify the sensitivity of national estimates to uncertainty in source rates and adjustment assumptions. However, simulated intervals based on assumed parameter ranges are not automatically equivalent to validated statistical confidence intervals. For ultra rare conditions, uncertainty may be particularly sensitive to survival, cumulative historical reports, and geographic concentration. Source-specific uncertainty should therefore be preserved rather than concealed through whole-number presentation.
Reporting Standards
The 2026 STROBE EPIC extension provides an especially relevant reference for future GNPTM™ applications. Murthy et al. (2026) identified the need for clearer reporting of prevalence denominators, case ascertainment, underdiagnosis corrections, surveillance limitations, and epidemiological comparability. GNPTM™ incorporates these issues into its proposed internal documentation. Source definitions, observation periods, population eligibility, adjustment assumptions, and evidence provenance should remain recoverable even where the public database presents a simplified prevalence estimate.
Validation should also include component level comparisons. Removing a terrain adjustment or replacing a diagnostic correction with a neutral coefficient can help determine whether each component improves or weakens predictive performance. GNPTM™ v1.2 remains a proposed integrated modeling framework. Empirical calibration and independent validation are required before claims of improved predictive performance can be established.
8. CYNAERA Framework Integration
GNPTM™ forms part of CYNAERA's broader population modeling architecture. Its contribution is the translation of international epidemiological evidence into national disease-burden estimates, rather than the general replacement of existing domestic prevalence research. US-CCUC™ examines undercounting in U.S. chronic-condition prevalence estimates.
Diagnostic Multiplier™ addresses the influence of diagnostic recognition and ascertainment on documented disease populations. GNPTM™ extends these concepts to conditions with stronger international than domestic evidence.
CCUC-Global™ provides a terrain-based international comparison framework developed in connection with CYNAERA's global ME/CFS prevalence research. GNPTM™ incorporates relevant terrain principles without transferring disease-specific ME/CFS prevalence percentages to unrelated conditions.
CGPI™ contributes information about cultural and sex-related patterns that may influence diagnostic visibility. These inputs are considered where relevant and are not automatically treated as changes in underlying biological prevalence.
PCT™ contributes an approach to evaluating initiating triggers, physiological vulnerabilities, environmental exposure, and persistence-related conditions. Its role within GNPTM™ is limited to circumstances where those mechanisms have a plausible and supportable relationship with the number of people living with the disease.
The broader international epidemiological literature provides support for using multiple complementary forms of evidence. The Global Burden of Disease Study incorporates surveillance, surveys, registries, clinical informatics, and modeled estimates within a coordinated research architecture (GBD 2021 Diseases and Injuries Collaborators, 2024).
Orphanet and related rare-disease information systems provide another important foundation by integrating disease nomenclature, epidemiology, genetics, and clinical information across multiple countries (Rath et al., 2012; Nguengang Wakap et al., 2020).
Integrated Research Architecture
National and International Epidemiology ↓ Diagnostic Ascertainment Assessment ↓ US-CCUC™ and Diagnostic Multiplier™ ↓ Population and Terrain Comparability ↓ CCUC-Global™ / CGPI™ / PCT™ ↓ GNPTM™ Population Translation ↓ Tier-Matched Ultra-Rare Pathway ↓ National Prevalence Estimates
These components are integrated selectively. Not every estimate requires every framework, and overlapping parameters must be reconciled before combination. The CYNAERA U.S. Chronic Condition Prevalence Database™ provides an application environment for evaluating the architecture across an expanding range of diseases. Its current coverage of more than 1,000 chronic conditions supports continued investigation into diagnostic undercounting, international prevalence differences, and the limitations of existing disease measurement systems.
9. Research Applications and Licensing
GNPTM™ supports epidemiological applications in which international disease evidence exists but direct national population estimates are limited or unavailable. International disease-burden modeling is an established field with substantial applications in research and health planning. The Global Burden of Disease Study and IARC's GLOBOCAN program demonstrate how standardized international evidence can inform comparisons across countries and disease categories (GBD 2021 Diseases and Injuries Collaborators, 2024; Sung et al., 2021).
GNPTM™ addresses a narrower but complementary problem: estimating condition-specific national prevalence when the underlying evidence is incomplete, geographically uneven, or affected by diagnostic differences. For rare-disease researchers, the framework may support identification of populations that warrant further epidemiological study or specialized registry development. For clinical research programs, projected population counts may inform preliminary trial feasibility assessments, although modeled estimates do not establish the number of confirmed or recruitable patients. For public health organizations, GNPTM™ may support evaluation of discrepancies between domestic surveillance and international research. Such comparisons can help identify areas in which improved population measurement may be warranted.
The Tier Matched Ultra Rare Estimation Pathway offers a specialized application for disorders represented primarily through case reports and small clinical cohorts. These analyses are particularly sensitive to source-population eligibility, genetic comparability, and survival assumptions, making transparent uncertainty assessment essential. CYNAERA may offer GNPTM™ through several licensing arrangements, including condition-specific prevalence analyses, specialty-level datasets, country-specific modeling contracts, institutional research subscriptions, and enterprise analytical deployment. The model's ultra-rare pathway may also support specialized research contracts involving orphan-disease population estimation and early clinical development planning. Proprietary calibration systems, implementation tools, and expanded datasets remain independently controlled CYNAERA assets.
10. Conclusion
National prevalence estimation is constrained by differences in epidemiological surveillance, diagnostic recognition, population composition, and the availability of disease-specific evidence. International research can provide valuable information where domestic estimates are missing, but transferring reported rates across countries without appropriate adjustment can produce misleading population counts. The Global to National Prevalence Translation Model (GNPTM™) establishes a structured approach to this challenge. By distinguishing international evidence quality, diagnostic ascertainment, population eligibility, and disease-relevant terrain, the framework provides a methodology for developing national prevalence projections under incomplete data conditions.
A complementary Tier Matched Ultra Rare Estimation Pathway supports population estimation for conditions with fewer than 100 documented patients worldwide, for which conventional population-based evidence may be absent. The pathway incorporates source-population identification, survival considerations, biological comparability, terrain adjustment, and fractional expected case handling. The model draws on established principles of prevalence estimation, evidence synthesis, diagnostic ascertainment, population genetics, rare event statistics, and international disease-burden research. Its distinctive contribution is the integration of these considerations into a modular framework for international to national prevalence translation.
GNPTM™ is intended to complement, not replace, established epidemiological surveillance. Its predictive performance remains subject to condition specific calibration, sensitivity analysis, and external validation. These evaluations will determine where the framework improves upon conventional international prevalence extrapolation and where simpler methods remain preferable. The framework provides a foundation for continued research within the CYNAERA U.S. Chronic Condition Prevalence Database™ and for broader applications involving international epidemiology, rare-disease population estimation, and licensed population intelligence.
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk. In 2026, she also served as an Advisor for the HHS TOPx AI and Tech Sprint, advising teams across the Invisible Illness, Cost of Illness, and Lyme disease tracks. Her contributions focused on patient centered AI development, disease burden modeling, federal data applications, and ensuring that emerging technologies reflected the experiences and priorities of people living with complex chronic conditions.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Barendregt, J. J., Doi, S. A., Lee, Y. Y., Norman, R. E., & Vos, T. (2013). Meta-analysis of prevalence. Journal of Epidemiology and Community Health, 67(11), 974–978. https://doi.org/10.1136/jech-2013-203104
Centers for Disease Control and Prevention. (2012). Principles of epidemiology in public health practice (3rd ed.). U.S. Department of Health and Human Services. https://archive.cdc.gov/www_cdc_gov/csels/dsepd/ss1978/lesson3/section2.html
Faye, F., Crocione, C., Anido de Peña, R., et al. (2024). Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: Results of a Rare Barometer retrospective patient survey. European Journal of Human Genetics, 32, 1116–1126. https://doi.org/10.1038/s41431-024-01604-z
GBD 2021 Diseases and Injuries Collaborators. (2024). Global incidence, prevalence, years lived with disability, disability-adjusted life-years, and healthy life expectancy for 371 diseases and injuries in 204 countries and territories, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet, 403, 2133–2161. https://doi.org/10.1016/S0140-6736(24)00757-8
GBD 2021 Risk Factors Collaborators. (2024). Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet, 403, 2162–2203. https://doi.org/10.1016/S0140-6736(24)00933-4
Haendel, M., Vasilevsky, N., Unni, D., et al. (2020). How many rare diseases are there? Nature Reviews Drug Discovery, 19, 77–78. https://doi.org/10.1038/d41573-019-00180-y
Hickie, I., Davenport, T., Wakefield, D., et al. (2006). Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: Prospective cohort study. BMJ, 333, 575. https://doi.org/10.1136/bmj.38933.585764.AE
Hook, E. B., & Regal, R. R. (1995). Capture-recapture methods in epidemiology: Methods and limitations. Epidemiologic Reviews, 17(2), 243–264. https://doi.org/10.1093/oxfordjournals.epirev.a036192
Hoy, D., Brooks, P., Woolf, A., et al. (2012). Assessing risk of bias in prevalence studies: Modification of an existing tool and evidence of interrater agreement. Journal of Clinical Epidemiology, 65(9), 934–939. https://doi.org/10.1016/j.jclinepi.2011.11.014
King, G., & Zeng, L. (2001). Logistic regression in rare events data. Political Analysis, 9(2), 137–163. https://doi.org/10.1093/oxfordjournals.pan.a004868
Manrai, A. K., Funke, B. H., Rehm, H. L., et al. (2016). Genetic misdiagnoses and the potential for health disparities. New England Journal of Medicine, 375, 655–665. https://doi.org/10.1056/NEJMsa1507092
Martin, A. R., Kanai, M., Kamatani, Y., et al. (2019). Clinical use of current polygenic risk scores may exacerbate health disparities. Nature Genetics, 51, 584–591. https://doi.org/10.1038/s41588-019-0379-x
Munn, Z., Moola, S., Lisy, K., Riitano, D., & Tufanaru, C. (2015). Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. International Journal of Evidence-Based Healthcare, 13(3), 147–153. https://doi.org/10.1097/XEB.0000000000000054
Murthy, S., Marchello, C. S., Hagedoorn, N. N., et al. (2026). Strengthening the Reporting of Observational Studies in Epidemiology Enhanced Prevalence and Incidence Criteria (STROBE EPIC): An extension of the STROBE statement. Annals of Internal Medicine, 179(9), 1280–1289. https://doi.org/10.7326/ANNALS-25-02412
Nguengang Wakap, S., Lambert, D. M., Olry, A., et al. (2020). Estimating cumulative point prevalence of rare diseases: Analysis of the Orphanet database. European Journal of Human Genetics, 28, 165–173. https://doi.org/10.1038/s41431-019-0508-0
Orphadata. (2026). Epidemiology of rare diseases: Orphanet epidemiological data resources. https://sciences.orphadata.com/epidemiology/
Popejoy, A. B., & Fullerton, S. M. (2016). Genomics is failing on diversity. Nature, 538, 161–164. https://doi.org/10.1038/538161a
Rath, A., Olry, A., Dhombres, F., Brandt, M. M., Urbero, B., & Aymé, S. (2012). Representation of rare diseases in health information systems: The Orphanet approach to serve a wide range of end users. Human Mutation, 33(5), 803–808. https://doi.org/10.1002/humu.22078
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011). Interpretation of random effects meta-analyses. BMJ, 342, d549. https://doi.org/10.1136/bmj.d549
Su, Y., Yuan, D., Chen, D. G., et al. (2022). Multiple early factors anticipate post-acute COVID-19 sequelae. Cell, 185(5), 881–895.e20. https://doi.org/10.1016/j.cell.2022.01.014
Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
United Nations, Department of Economic and Social Affairs, Population Division. (2024). World Population Prospects 2024. https://population.un.org/wpp/
U.S. Census Bureau. (2026). QuickFacts: United States. https://www.census.gov/quickfacts/USA
Comments